14271-35-3

Upstream product

• 124862-62-0 2-acetoxy-2-(3-chlorophenyl)acetonitrile 
• 1529-41-5 3-chloro-benzeneacetonitrile 
• 74-88-4 methyl iodide 
• 766-84-7 3-chloro-benzonitrile 
• 1013479-86-1 N'-(1-(3-chlorophenyl)ethylidene)-4-methylbenzenesulfonohydrazide 
• 333-20-0 potassium thioacyanate 
• 67-56-1 methanol 

Downstream Products

• 14161-84-3 2-(3-chlorophenyl) propanoic acid 
• 14161-84-3 (S)-(+)-2-(3'-chlorophenyl)propanoic acid 
• 14161-87-6 1-Chloro-3-((Z)-1-methyl-2-phenyl-propenyl)-benzene 
• 14161-86-5 1-Chloro-3-(1-methyl-2-phenyl-allyl)-benzene 
• 14161-85-4 2-(3-chlorophenyl)propiophenone 
• 1421692-18-3 (S)-2-(3-chlorophenyl)propanenitrile 
• 1421691-96-4 1-tert-butyl-N-(2-(3-chlorophenyl)prop-1-en-1-ylidene)-1,1-dimethylsilanamine 
• 1440519-50-5 2-(3-chlorophenyl)propan-1-amine hydrochloride salt 
• 1082555-06-3 2-(3-chlorophenyl) propan-1-amine 
• 1609270-83-8 C₂₁H₁₇ClN₄OS 
• 103040-42-2 (S)-methyl 2-(3-chlorophenyl)propanoate 

Relevant academic research and scientific papers

Base-controlled chemoselectivity: direct coupling of alcohols and acetonitriles to synthesise α-alkylated arylacetonitriles or acetamides

We achieved chemoselective synthesis of α-alkylated arylacetonitriles and acetamides by combining Ir complex-catalysed direct coupling of alcohols and nitriles by a simple adjustment of the base. Methanol and ethanol performed well as the alkylating reagents. This method of acetonitrile alkylation provided a novel approach for carbon chain extension.

Rhenium(I)-Catalyzed C-Methylation of Ketones, Indoles, and Arylacetonitriles Using Methanol

A ReCl(CO)5/MeC(CH2PPh2)3 (L2) system was developed for the C-methylation reactions utilizing methanol and base, following the borrowing hydrogen strategy. Diverse ketones, indoles, and arylacetonitriles underwent mono-and dimethylation selectively up to 99% yield. Remarkably, tandem multiple methylations were also achieved by employing this catalytic system.

A novel route to (R)-2-(3-chlorophenyl)propan-l-amine, a key intermediate for the synthesis of lorcaserin

A new and efficient three-step synthesis of (R)-2-(3-chlorophenyl)propan-l-amine is reported, which serves as an intermediate in the synthesis of the antiobesity drug lorcaserin. The key step is a chiral resolution due to the formation of a salt with l-(-

Copper-Catalyzed Cyanation of N-Tosylhydrazones with Thiocyanate Salt as the "cN" Source

A novel protocol for the synthesis of α-aryl nitriles has been successfully achieved via a copper-catalyzed cyanation of N-tosylhydrazones employing thiocyanate as the source of cyanide. The features of this method include a convenient operation, readily available substrates, low-toxicity thiocyanate salts, and a broad substrate scope.

Cyanide-Free and Broadly Applicable Enantioselective Synthetic Platform for Chiral Nitriles through a Biocatalytic Approach

A cyanide-free platform technology for the synthesis of chiral nitriles by biocatalytic enantioselective dehydration of a wide range of aldoximes is reported. The nitriles were obtained with high enantiomeric excess of >90 % ee (and up to 99 % ee) in many cases, and a “privileged substrate structure” with respect to high enantioselectivity was identified. Furthermore, a surprising phenomenon was observed for the enantiospecificity that is usually not observed in enzyme catalysis. Depending on whether the E or Z isomer of the racemic aldoxime substrate was employed, one or the other enantiomer of the corresponding nitrile was formed preferentially with the same enzyme.

PREPARATION OF CHIRAL 1-METHYL-2,3,4,5-1H-BENZODIAZEPINES VIA ASYMMETRIC REDUCTION OF ALPHA-SUBSTITUTED STYRENES

The present invention provides an asymmetric and economic synthesis of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H-benzo[d]azepine via novel intermediates applying an asymmetric enzymatic, biomimetic or catalytic reduction. The present invention also provides a novel green asymmetric catalytic reduction adapted for an aqueous medium to be applied in the synthesis of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H-benzo[d]azepine or novel intermediates.

NOVEL SYNTHETIC PROCESS TO 8-CHLORO-1-METHYL-BENZO[D]AZEPINE, NOVEL INTERMEDIATES AND THE PRODUCTION THEREOF

The present invention is directed to a simple and economical process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine via novel intermediates and a highly selective asymmetric synthesis leading to enantiopure (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d] azepine or its (S)-enantiomer, in order to avoid or overcome chemical optical resolution.

LORCASERIN HYDROCHLORIDE

The present invention relates to amorphous lorcaserin hydrochloride; amorphous solid dispersion comprising lorcaserin hydrochloride and one or more pharmaceutically acceptable carries; processes for preparation thereof; pharmaceutical compositions comprising amorphous lorcaserin hydrochloride and one or more pharmaceutically acceptable carries.

INHIBITORS OF CYTOMEGALOVIRUS

Compounds of Formula (I) wherein n, R1, R1A, R2, R3, Y and Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.

Structure-activity relationship of N,N′-disubstituted pyrimidinetriones as CaV1.3 calcium channel-selective antagonists for Parkinson's disease

CaV1.3 L-type calcium channels (LTCCs) have been a potential target for Parkinson's disease since calcium ion influx through the channel was implicated in the generation of mitochondrial oxidative stress, causing cell death in the dopaminergic neurons. Selective inhibition of CaV1.3 over other LTCC isoforms, especially CaV1.2, is critical to minimize potential side effects. We recently identified pyrimidinetriones (PYTs) as a CaV1.3-selective scaffold; here we report the structure-activity relationship of PYTs with both CaV1.3 and CaV1.2 LTCCs. By variation of the substituents on the cyclopentyl and arylalkyl groups of PYT, SAR studies allowed characterization of the CaV1.3 and Ca V1.2 LTCCs binding sites. The SAR also identified four important moieties that either retain selectivity or enhance binding affinity. Our study represents a significant enhancement of the SAR of PYTs at CaV1.3 and CaV1.2 LTCCs and highlights several advances in the lead optimization and diversification of this family of compounds for drug development.